Cavosonstat

N/A

Report date: 2026/01/16 20:01:23
NME

Base Information

Drug NameCavosonstat
Drug Alias NameN-91115PBA-003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulatorsS-nitroso glutathione reductase inhibitors
TargetsCystic fibrosis transmembrane conductance regulatorS-nitroso glutathione reductase
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsPulmonary Disease, Chronic ObstructiveAsthma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPending
Originator CompaniesNivalis Therapeutics, Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesUniversity Of North Carolina At Chapel Hill
Inactive CompaniesLangyu Pharmaceutical Technology (Hangzhou) Co LtdNivalis Therapeutics, IncGSNOR Therapeutics Inc
Active IndicationsAsthma
Inactive IndicationsDrug-Related Side Effects and Adverse ReactionsPulmonary Disease, Chronic ObstructiveCystic Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A